Pomerantz investigates Galectin Therapeutics for potential securities fraud.

Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. regarding potential securities fraud and unlawful business practices. The investigation concerns a December 2025 press release announcing the FDA's response to Galectin's Type C meeting request regarding belapectin, a galectin-3 inhibitor. Galectin will pursue a follow-up written response from the FDA. Investors who wish to join the class action should contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.